Trial Profile
A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisolone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 01 Apr 2021 Primary endpoint has been met. (Percentage of Participants Achieving Prostate-specific Antigen (PSA) Response (PSA Response Rate) by 12 Weeks of Therapy), as per Results published in the Japanese Journal of Clinical Oncology
- 01 Apr 2021 Results published in the Japanese Journal of Clinical Oncology
- 28 Feb 2018 Status changed from active, no longer recruiting to completed.